

Supplementary table 1. References for the elaboration of prior distributions for sensitivity (Se) and specificity (Sp) for intradermal (CFT, CFT-CCT) and in-vitro (IGRAb, IGRAc, ELISA) diagnostic tests evaluated.

Test	Antigen	Cutoff	Se	95CI	Sp	95CI	Characteristics	Reference (et al.)	Year	Origin	
CFT	Any palpable increase	76	56	89	100	92	100	Meta-analysis	Nuñez-Garcia	2018	UK & Ireland
		85.7			92.6			Meta-analysis	Farnaham	2011	USA
		83.33	51.59	97.91				Study	Norby	2004	USA
		80.4						Study	Whipple	1995	USA
		82			96			Review	USDA-APHIS	1992	USA
		65.6	56.6	73.9				Study	Wood	1991	Australia
		81.8			96.3			Study	Francis	1978	Australia
		CFT-CCT	>4mm	50	26	78	100	99	100	Meta-analysis	Nuñez-Garcia
53	46			62				Study	VanderWaal	2017	Uruguay
55.1-93.5					88.8-100			Review	Vordemeier	2006	Global
75	42.81			94.51				Study	Norby	2004	USA
IGRA	PPDb-PPDa (IGRAb)	60.7	48	72				Study	Casal	2014	Spain
		83.5	73.6	91.6	90.4	89.1	92.7	Study	Alvarez	2012	Spain
		87.6	73	100	96.6	85	99.6	Review	de la Rua Domenech	2006	Global
		88			95			Study	Gomley	2006	Ireland
		66			84			Study	Aagaard	2006	Global
		85	72	90	93	89	96	Study	Ryan	2000	New Zealand
IGRA	Peptide-Cocktail (IGRAc)	78	60	90	99	99	100	Meta-analysis	Nuñez-Garcia	2018	UK & Ireland
		80			100			Study	Flores-Villalba	2012	Mexico
		85	73	94	97	94	100	Study	Aagaard	2006	Global
ELISA	MPB83-MPB70	61.1	33.1	84.6	85.4	81.7	88.8	Study	Al-Mouqatea	2018	Kuwait
		57.1	44	69	100			Study	Casal	2012	Spain
		18.1			96.4			Study	Wood	1992	Australia
		61.9	30	96.7	98.2	93.8	100	Review	Waters	2012	UK,Ireland,NZ,USA

Supplementary table 2. Results from the sensitivity analyses using uniform distributed priors for sensitivity (Se), specificity (Sp), and Prevalence (prev) for each bTB-diagnostic test evaluated.

Reference values indicate posterior median results and posterior probability intervals (LowPPI, HighPPI) for the model including informative priors.

The table is shown in the Excel file.